Centring women’s voices in contraceptive innovation: building the case for an on-demand, pericoital pill (2024)

Centring women’s voices in contraceptive innovation: building the case for an on-demand, pericoital pill (1)

  • Subscribe
  • Log In More

    Log in via Institution

    Log in via OpenAthens

    Log in via FSRH

    Log in using your username and password

  • Basket
  • Search More

    Advanced search

  • Latest content
  • Current issue
  • Archive
  • Authors
  • About

Advanced search

You are here

  • Home
  • Online First
  • Centring women’s voices in contraceptive innovation: building the case for an on-demand, pericoital pill

Email alerts

Article Text

Article menu

  • Article Text
  • Article info
  • Citation Tools
  • Share
  • Rapid Responses
  • Article metrics
  • Alerts

Editorial

Centring women’s voices in contraceptive innovation: building the case for an on-demand, pericoital pill

  1. GIlda Sedgh1,
  2. Laura J Frye2,
  3. http://orcid.org/0000-0001-6516-1444Kristina Gemzell-Danielsson3,
  4. http://orcid.org/0000-0002-9602-3674Nathalie Kapp4,
  5. Kayode Afolabi5,
  6. Angela A Boateng6,
  7. Mary Mulombe-Phiri7,
  8. http://orcid.org/0000-0002-1168-2276Sharon Cameron8,9,
  9. Kanya Manoj10,
  10. Kirti Iyengar10,
  11. http://orcid.org/0009-0005-7851-0283Abigail Grace Winskell11,
  12. http://orcid.org/0009-0002-3261-8078Kristen M Little12,
  13. http://orcid.org/0000-0003-0465-2586Susannah Gibbs12,
  14. Eden Demise12,
  15. Stephen Bell13,14
    1. 1Evidence & Learning Working Group, Self-Care Trailblazers Group, Philadelphia, Pennsylvania, USA
    2. 2FHI 360, Durham, North Carolina, USA
    3. 3Women's and Children's Health, Karolinska Institute, Stockholm, Sweden
    4. 4International Planned Parenthood Federation, London, UK
    5. 5Independent Consultant, Abuja, Nigeria
    6. 6Ghana Health Service, Accra, Ghana
    7. 7Reproductive Health Directorate, Government of Malawi Ministry of Health, Lilongwe, Malawi
    8. 8Sexual and Reproductive Health, NHS Lothian, Edinburgh, UK
    9. 9University of Edinburgh Division of Health Sciences, Edinburgh, UK
    10. 10Children's Investment Fund Foundation, London, UK
    11. 11Sexual & Reproductive Health, Population Services International, Washington, District of Columbia, USA
    12. 12Strategy & Insights Department, Population Services International, Washington, District of Columbia, USA
    13. 13Independent Consultant, Melbourne, Victoria, Australia
    14. 14Women’s, Children’s and Adolescents’ Health, Burnet Institute, Melbourne, Victoria, Australia
    1. Correspondence to Dr Kristen M Little; klittle{at}psi.org

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      • scoping review
      • on-demand contraception
      • family planning
      • contraceptive preferences
      • emergency contraception
      • pericoital contraceptive
      • reproductive health
      • new contraceptive methods
      • sexual agency

      Despite growing support for reproductive autonomy globally1 2 and the push to achieve the United Nations (UN) Sustainable Development Goals Target 3.7 (ensuring universal access to sexual and reproductive healthcare services), progress in meeting people’s contraceptive needs has been slow. Recent estimates indicate that 218 million women of reproductive age in low- and middle-income countries still have an unmet need for modern contraception – that is, they wish to avoid a pregnancy but are not using a modern method.3

      While the level of unmet need for contraception has hardly shifted in recent years, women’s reasons for not using a contraceptive method have changed.4 In 2016, an analysis of survey data from 39 countries from 2000 onwards4 found that a small, shrinking proportion of women say they lack knowledge of contraception or access to contraceptive care, while a sizeable, growing proportion of women say they are not using a method because those available do not suit their needs. Infrequent or no sex was one of the two most cited reasons for not using a method (along with concerns about method side effects or health risks), mentioned by 24% of married women and 41% of unmarried women.4 Among their recommendations, the authors suggested that investments in new, more user-aligned, contraceptive methods could address women’s needs and concerns.4

      Development of an ‘on-demand’ (defined as coitally-dependent usage) oral contraceptive pill that could be taken pericoitally (ie, before or after sex) represents one such innovation. Several recent studies have contributed to the body of evidence suggesting that these on-demand pills can be efficacious,5 6 feasible,7 8 acceptable6–8 and safe with limited side effects.6–8 Although on-demand pericoital pills may be less effective at preventing pregnancy than many available long-acting reversible contraceptives, some women and other individuals at risk of pregnancy are likely willing to make trade-offs between level of effectiveness and the ability to avoid some side effects, the costs associated with use of a continuous method, and to have control over when they start and stop using a method. For those people having infrequent sex, who are already at a lower overall risk of pregnancy, the impact of a less effective method may be more limited.

      A recently published systematic scoping review of 30 papers published between 2014 and 2023 from 16 countries across five WHO regions indicates widespread appeal among women for an on-demand contraceptive pill.9 The analysis found that use of an on-demand pericoital contraceptive pill aligned more closely with some women’s sexual lives, particularly those who reported having occasional or spontaneous sex, or who could not plan for sex. The review also found that discreet, routine postcoital use of the emergency contraceptive pill (further supported by convenient over-the-counter availability in many settings) enabled some women to navigate circumstances in which their reproductive agency was constrained.

      Together, these rationales point to the potential benefits of an on-demand contraceptive pill to satisfy the demand for contraception among many non-users at risk of unintended pregnancy, and to support their agency in their sexual and reproductive decision-making and action. Regular use of available postcoital contraceptive pills could address some of these barriers, and introduction of a pericoital product that could be used before or after sex as a person’s main form of contraception would have several advantages. These include the option for advanced provision, availability of a method less burdened by stigma around ‘over-use’ of a product intended only for emergencies, and the ability to enter potential sexual encounters knowing they have already taken measures to prevent unintended pregnancy.

      Further contraceptive innovation is required to expand the range of affordable, acceptable and accessible contraceptive products and technologies that enhance women’s and girls’ control over their own contraceptive care, in ways that meet their needs. The addition of an on-demand contraceptive pill to the current method mix responds not only to longstanding global calls, commitments and movements for sexual and reproductive justice and equity, but also to the voices of women themselves.

      We encourage funders to recognise the potential of on-demand contraceptive products, support ongoing work to confirm their safety, efficacy and user acceptability, and bring such a product to market. More broadly, we encourage research on new methods, and innovations that leverage existing contraceptive technologies, to meet the needs of people whose circumstances are not well-aligned with the current range of contraceptive options. Together, these efforts have the potential to fill a critical gap in contraceptive markets for those who currently find themselves dissatisfied with current contraceptive options that do not align with their lived experiences and expressed needs.

      Ethics statements

      Patient consent for publication

      Not applicable.

      Ethics approval

      Not applicable.

      References

        1. Starrs AM,
        2. Ezeh AC,
        3. Barker G, et al

        . Accelerate progress—sexual and reproductive health and rights for all: report of the Guttmacher– Lancet Commission. Lancet 2018;391:264292. doi:10.1016/S0140-6736(18)30293-9

        OpenUrlCrossRefPubMed

        1. United Nations (UN)

        . Report of the International Conference on Population and Development, Cairo, 5–13 September 1994. New York UN; 1995. Available: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/a_conf.171_13_rev.1.pdf [accessed 9 Oct 2024]

        1. Sully EA,
        2. Biddlecom A,
        3. Darroch JE, et al

        . Adding it up: investing in sexual and reproductive health 2019. July 28, 2020. doi:10.1363/2020.31593

        1. Sedgh G,
        2. Ashford LS,
        3. Hussain R

        . Unmet need for contraception in developing countries: examining women’s reasons for not using a method. Available: https://www.guttmacher.org/report/unmet-need-for-contraception-in-developing-countries [Accessed 9 Oct 2024].

        1. Cahill EP,
        2. Lerma K,
        3. Shaw KA, et al

        . Potential candidate for oral pericoital contraception: evaluating ulipristal acetate plus cyclo-oxygenase-2 inhibitor for ovulation disruption. BMJ Sex Reprod Health 2022;48:21721. doi:10.1136/bmjsrh-2021-201446

        OpenUrlAbstract/FREE Full Text

        1. Festin MPR,
        2. Bahamondes L,
        3. Nguyen TMH, et al

        . A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg. Hum Reprod 2016;31:53040. doi:10.1093/humrep/dev341

        OpenUrlCrossRefPubMed

        1. McCann B,
        2. Liang T,
        3. Ramarao S, et al

        . Feasibility and Acceptability of LNG 1.5 mg as an On-Demand Pericoital Contraceptive in Ghana. Stud Fam Plann 2023;54:52338. doi:10.1111/sifp.12248

        OpenUrlPubMed

        1. Odwe G,
        2. McCann B,
        3. Liambila W, et al

        . Feasibility of e-commerce pharmacy provision and acceptability of levonorgestrel 1.5 mg for pericoital use in urban and peri-urban settings in Kenya: a prospective cohort study. BMJ Sex Reprod Health 2023;49:3542. doi:10.1136/bmjsrh-2022-201653

        OpenUrlAbstract/FREE Full Text

        1. Bell S,
        2. Gibbs S,
        3. Winskell A, et al

        . Acceptability of an on-demand pericoital oral contraceptive pill: a systematic scoping review. Reprod Health 2024;21:93. doi:10.1186/s12978-024-01829-7

      Footnotes

      • Contributors All authors contributed meaningfully to the conception, writing and/or editing of this editorial. SB led the writing with support from GS and LJF. All authors reviewed paper drafts, provided written inputs and edits, and approved the final version for submission. KML is the guarantor.

      • Funding This work was supported with funding from the Bill and Melinda Gates Foundation (INV053495) and the Children’s Investment Fund Foundation (2210-08074)

      • Competing interests SC is the Editor-in-Chief of BMJ SRH. This work was funded in part by a grant from the Children’s Investment Fund Foundation (CIFF). KI and KM are CIFF employees involved in this grant. The authors have no other competing interests to declare.

      • Provenance and peer review Not commissioned; externally peer reviewed.

      Read the full text or download the PDF:

      Subscribe

      Log in via Institution

      Log in via OpenAthens

      Log in via FSRH

      Log in using your username and password

      Centring women’s voices in contraceptive innovation: building the case for an on-demand, pericoital pill (2024)
      Top Articles
      Latest Posts
      Recommended Articles
      Article information

      Author: Velia Krajcik

      Last Updated:

      Views: 6704

      Rating: 4.3 / 5 (74 voted)

      Reviews: 89% of readers found this page helpful

      Author information

      Name: Velia Krajcik

      Birthday: 1996-07-27

      Address: 520 Balistreri Mount, South Armand, OR 60528

      Phone: +466880739437

      Job: Future Retail Associate

      Hobby: Polo, Scouting, Worldbuilding, Cosplaying, Photography, Rowing, Nordic skating

      Introduction: My name is Velia Krajcik, I am a handsome, clean, lucky, gleaming, magnificent, proud, glorious person who loves writing and wants to share my knowledge and understanding with you.